TrialsTrialsTrials
 Amy E. Veroff, PhD joins CogState as Consultant Neuropsychologist

Amy E. Veroff, PhD has joined CogState as Consultant Neuropsychologist and clinical trials expert. With more than 30 years’ experience in clinical and research settings, she is licensed in Massachusetts, Maryland, and California. She previously held a clinical appointment in the Neurology Department at Boston University Medical School and an academic appointment in the Department of Psychiatry and Behavioral Sciences at Johns Hopkins University Medical School, providing clinical services, teaching medical students, graduate students in psychology and post-doctoral fellows, and researching dementia and other neuropsychiatric disorders. At Johns Hopkins, she was principal investigator of a grant studying the dementia syndromes of Huntington’s and Alzheimer’s diseases.

Dr. Veroff has provided specialized services related to the use of scales in clinical drug trials for nearly 25 years, and established and led a global CRO division providing these services. Under Dr. Veroff’s leadership, the group provided rater training programs, quality control of study data, translation, harmonization, and cultural adaptation of scales, cognitive testing technology, and other related scales services for more than 200 clinical trials, training more than 20,000 raters worldwide.

Dr. Veroff serves on the Alzheimer’s Disease Cooperative Study (ADCS) Workgroup, tasked with updating the ADAS-cog. Dr. Veroff is widely published and co-authored a book on Alzheimer’s disease clinical trials, Alzheimer’s Disease: Optimizing Drug Development Strategies. Dr. Veroff designed and co-pioneered the Computerized Neuropsychological Test Battery (CNTB), a tool for assessment of CNS-drug effects and she brings to CogState a keen interest in developing and implementing innovative computer technologies to improve quality in the use of traditional paper and pencil neuropsychological tests. Dr. Veroff has dedicated the majority of her long professional career to the support of the scientific investigation of potential drug therapies for Alzheimer’s disease.

Contact